ESMO Targeted Anticancer Therapies Congress 2023
![Proffered paper_Q&A_TAT 2023](/var/esmo/storage/images/media/esmo-daily-reporter/images/tat-2023/proffered-paper_q-a_tat-2023/17345081-1-eng-GB/proffered-paper_q-a_tat-2023_i770.jpg)
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
![Proferred paper_TAT 2023](/var/esmo/storage/images/media/esmo-daily-reporter/images/tat-2023/proferred-paper_tat-2023/17345066-1-eng-GB/proferred-paper_tat-2023_i770.jpg)
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
![Mini Oral_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/tat-2023/mini-oral_01/17337797-1-eng-GB/mini-oral_01_i770.jpg)
New tools and methods are discussed for optimising investigation of precision therapeutics
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
![DNA_sequencing](/var/esmo/storage/images/media/esmo-daily-reporter/images/editorials/dna_sequencing/17328602-1-eng-GB/dna_sequencing_i770.jpg)
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
![TAT 2023_audience](/var/esmo/storage/images/media/esmo-daily-reporter/images/tat-2023/tat-2023_audience/17337869-1-eng-GB/tat-2023_audience_i770.jpg)
Early phase cancer research – ready for a change?
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
![Andrés Cervantes - Official 2023](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/andres-cervantes-official-2023/17927117-1-eng-GB/andres-cervantes-official-2023_i770.jpg)
Improving collaboration to expedite early-phase research in oncology
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
![Epigenetic therapies – have they come of age?](/var/esmo/storage/images/esmo-daily-reporter/esmo-targeted-anticancer-therapies-congress-2023/esmo-tat-congress-2023/epigenetic-therapies-have-they-come-of-age/17329202-4-eng-GB/epigenetic-therapies-have-they-come-of-age_i770.jpg)
Epigenetic therapies – have they come of age?
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies